Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Peripheral Artery Disease: Treatments And Diagnostics Poised For Growth

Executive Summary

The market for peripheral vascular interventions and diagnostics is poised for significant growth in the years ahead, driven by an aging population and the growing incidence of peripheral vascular disease, along with new technological developments such as drug-eluting balloons, which are inching closer to regulatory approval in the US.

You may also be interested in...



Market Update: Growth And Opportunities In Peripheral Artery Disease

Drug-coated balloon (DCBs) catheters have become the latest weapon in the fight against peripheral artery disease in the US, although they have been in use in Europe for some time. While the number of procedures employing DCBs is still dwarfed by conventional angioplasty procedures, they are expected to grow at a much faster rate, fueling a market projected to reach $1 billion by 2020; meanwhile other procedures such as mechanical atherectomy are also expected to show significant growth.

Medicare Advisors Lukewarm On Lower Extremity PAD Intervention Evidence

The Medicare Evidence Development and Coverage Advisory Committee voted low to moderate support for the scientific evidence backing endovascular and other interventions to treat lower extremity peripheral artery disease.

Boston Scientific Touts Data On "Purpose-Built" Drug-Eluting Peripheral Stent

The firm's Eluvia paclitaxel eluting stent, design for peripheral arteries, showed positive results in data from a small trial presented April 28 at the Charing Cross International Symposium in London.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT035803

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel